A Jumeirah 1 medical clinic with a first-party page for peptide and IV therapy programmes.
Availability does not establish approval or effectiveness. Ask for the exact active ingredient, product registration, indication, prescriber, dispensing source, risks, alternatives, and follow-up plan.
The clinic's page combines prescription-medicine pathways and compounds with limited evidence or unclear approval status. Exact product, formulation, indication, dispensing source, and UAE registration should be verified separately. Clinic service claims are not treated as independent clinical evidence.
MedPalm publicly lists multi-service programme prices from AED 8,800 to AED 12,300.
These are clinic-stated programme prices, not individual peptide prices. Programmes may include services beyond peptides; request an itemised written quote identifying the exact product, clinical services, monitoring and follow-up.
Price information is attributed to the clinic and may change. It does not establish medical approval, product registration, effectiveness or the total cost of care.
These labels assess the named molecule, not the clinic’s particular product, protocol or marketing claim. UAE registration remains product and indication specific.
| Peptide | Category | Evidence | Approval note | Editorial assessment |
|---|---|---|---|---|
| BPC-157 | Experimental compound | Preclinical | Not established as an approved human medicine | Most supportive claims rely on laboratory or animal research; robust clinical evidence and established approval are lacking. |
| GHK-Cu | Experimental compound | Limited | Depends on formulation and intended use | Cosmetic ingredient use is different from injected or systemic treatment claims. Evidence and regulation depend on formulation. |
| Kisspeptin | Experimental compound | Limited | Specialist or investigational context | Human research exists in reproductive endocrinology, but routine commercial wellness use is not established. |
| MOTS-c | Experimental compound | Preclinical | Not established as an approved human medicine | Metabolic and longevity claims remain predominantly experimental and are not established clinical outcomes. |
| Thymosin Beta-4 | Experimental compound | Limited | Exact product and use require verification | Research on thymosin beta-4 should not be treated as evidence for every product marketed as TB-500 or for broad recovery claims. |
| Tirzepatide | Prescription medicine | High | Product and indication specific | Supported by substantial human evidence for specific approved metabolic indications. Registration does not cover every promoted use. |
Confirm current hours with the clinic
+971 56 802 0088Compare clinical assessment, product traceability, informed consent, monitoring, adverse-event support, and alternatives—not marketing claims.
Is this information outdated? Send the editorial team a correction.Clinics cannot pay to change directory order or evidence classifications.